P232 A study to evaluate the safety and utility of targeted axillary dissection using Guiding-Marker System
Main Authors: | Y. Endo, H. Kotani, A. Nakakami, R. Komaki, A. Isogai, Y. Ozaki, K. Nozawa, A. Kataoka, A. Yoshimura, M. Hattori, M. Sawaki, H. Iwata |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2023-03-01
|
Series: | Breast |
Online Access: | http://www.sciencedirect.com/science/article/pii/S0960977623003508 |
Similar Items
-
P289 Retrospective study of pregnancy outcome after breast cancer
by: A. Yoshimura, et al.
Published: (2023-03-01) -
Single-dose trastuzumab monotherapy achieved pathological complete response (pCR) in a patient with HER2-positive breast cancer: a case report
by: Ayaka Isogai, et al.
Published: (2023-06-01) -
Triple HER2-blockade with lapatinib, trastuzumab, and pertuzumab for treatment of HER2 positive metastatic breast cancer with lymphangitic carcinomatosis: A case study
by: Kazuki Nozawa, et al.
Published: (2022-09-01) -
AN AXILLARY ARCH OF DEDECTED DURING AXILLARY DISSECTION
by: Bülent Koca, et al.
Published: (2011-10-01) -
Ideal marker for targeted axillary dissection (IMTAD): a prospective multicentre trial
by: Jan Žatecký, et al.
Published: (2023-08-01)